M2 Presswire - FTC charges drug manufacturers with stifling competition in two prescription drug markets; Complaint filed against Hoechst Marion Roussel, Inc. and Andrx…
Related Results
Boehringer, Abbott to co-promote Flomax - Brief Article
At work with… Stephen Neale
FDA Approves Three Hypertension Treatments.(Brief Article)(Statistical Data I…
Novartis settles dispute with FTC.(Brief Article)
FTC to Investigate Possible Pharma Collusion.(payoffs for delays of generic d…
> M2 PRESSWIRE-17 March 2000-US FTC: FTC charges drug manufacturers with stifling competition in two prescription drug markets; Complaint filed against Hoechst Marion Roussel, Inc. and Andrx Corp.; Proposed settlement reached with Abbott Laboratories and Geneva Pharmaceuticals, Inc. (C)1994-2000 M2 COMMUNICATIONS LTD RDATE:16032000 * Complaints Charge Multi-Million-Dollar Arrangements Were Designed to Keep Generic Versions of Cardizem CD and Hytrin Off the Market The Federal Trade Commission today charged two drug makers, Hoechst Marion Roussel (now Aventis) and Andrx …
Read the rest of this article with a Free Trial at HighBeam Research.
